An Open Label Phase I Dose Escalation Study Of E7080

Trial Profile

An Open Label Phase I Dose Escalation Study Of E7080

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2016

At a glance

  • Drugs Lenvatinib (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Eisai Inc
  • Most Recent Events

    • 19 Apr 2019 Planned End Date changed to 1 Dec 2016.
    • 27 Jul 2015 Status changed from active, no longer recruiting to completed according to results published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
    • 13 Jul 2015 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top